. Mutational antigenic profiling quantifies the antigenic effect of all amino-acid mutations to HA. We generate libraries of mutant viruses carrying all mutations to HA compatible with viral growth. We incubate the libraries with antibodies or serum, and infect cells with non-neutralized virus. Viral RNA from infected cells is deep sequenced to measure the frequency of each mutation. We quantify immune selection on each mutation as its log enrichment relative to wildtype in the immune-selected sample versus a mock-selection control. Data are displayed in logo plots, with larger letters indicating stronger immune selection for a mutation. ('lib1', 'lib2', or 'lib3') . These plots are replicate-to-replicate breakdowns of those in Figure 2A ,C except that the logo plots are colored by the physicochemical properties of amino acids rather than using the color scheme in the main figure. Note that Figure Neutralization assays validate that mutations mapped to be under strong immune selection indeed have large antigenic effects. The dashed vertical lines show the serum concentrations used in the mutational antigenic profiling. We validated five amino-acid mutants against all four sera, choosing mutations for the following reasons: F193D is the most strongly selected mutation for the 21-and 65-year-old, L157D is the most selected for the 53-year-old, F159G is the most selected for the 64-year-old, K160T is modestly selected by all sera, and K189D is strongly selected by ferret sera (see below). The 'syn' mutant is a control with a synonymous mutation does not change the protein sequence and so should not affect antigenicity. (C) Immune selection mapped onto HA's structure for each sera. The color scale is calibrated separately for each structure. For interactive versions of the structures, click https://mybinder.org/v2/gh/jbloomlab/map_flu_serum_Perth2009_H3_HA/master?urlpath=%2Fapps%2Fresults%2Fnotebooks%2Fmap_ on_struct_VIDD_sera.ipynb. Site 189 is shown in the logo plots despite not being a strongly selected site because it is important for ferret sera (see below ('lib1', 'lib2', or 'lib3') . These plots are replicate-to-replicate breakdowns of those in Figure 3A ,B except that the logo plots are colored by the physicochemical properties of amino acids rather than using the color scheme in the main figure. Note that Figure 3A displays the median of the replicates shown here. Site 189 is not shown in the logo plots here since it is not a strongly selected mutation for any of the human serum samples in this figure, and is shown in the main Figure 3B simply for comparative purposes with the ferret sera. The serum sample labeled '2009 age 53 plus 2 months' is that described in Figure 3 for the serum from the 53-year-old individual alongside comparable data generated using another serum sample from the same individual collected 2 months later. The dashed vertical lines on the neutralization curves show the serum concentrations used in the mutational antigenic profiling. The mutations chosen for validation by neutralization curves are the ones that the neutralization curves in Figure 3B found had an effect for sera from this individual. Percent of viral library retaining infectivity after serum treatment during mutational antigenic profiling. The percent of the mutant virus library that remained infectious after incubation with serum was determined using qPCR for each replicate of the mutational antigenic profiling. Higher serum concentrations generally lead to larger values of the immune selection measured in the mutational antigenic profiling. For the pre-vaccination samples from the 48-and 49-year-old individuals, we were unable to achieve a concentration that reduced the infectivity of the viral libraries to <10% because these sera were not very potent (
Figure 5B ('lib1', 'lib2', or 'lib3') . These plots are replicate-to-replicate breakdowns of those in Figure 5A except that the logo plots are colored by the physicochemical properties of amino acids rather than using the color scheme in the main figure. Note that Figure 5A ferret WHO Victoria2011
Figure 6-figure supplement 1. Percent of viral library retaining infectivity after serum treatment during mutational antigenic profiling. The percent of the mutant virus library that remained infectious after incubation with serum was determined using qPCR for each replicate of the mutational antigenic profiling. Higher serum concentrations generally lead to larger values of the immune selection measured in the mutational antigenic profiling. For the pre-infection samples, we were unable to achieve a concentration that reduced the infectivity of the viral libraries to <10% because these sera do not neutralize the virus ( Figure 6B ('lib1', 'lib2', or 'lib3') . These plots are replicate-to-replicate breakdowns of those in Figure 6A except that the logo plots are colored by the physicochemical properties of amino acids rather than using the color scheme in the main figure. Note that Figure 6A displays the median of the replicates shown here. (B) The Pearson correlation coefficients of the total immune selection at each site (height of the letter stack) computed over all sites for each pair of replicates. Note that the correlations are low for the pre-infection sera as these sera do not neutralize the virus and so do not consistently select any antigenic mutations. DOI: https://doi.org/10.7554/eLife.49324.018 A B Figure 7 . Mutational antigenic profiling of polyclonal human serum spiked with a monoclonal antibody. The antibody is spiked into the serum at a 'low' concentration (antibody alone less potent than serum alone), a 'mid' concentration (antibody similarly potent to serum), and a 'high' concentration (antibody more potent than serum); see Figure 7 -figure supplement 1 for details. (A) Line plots show the total immune selection at each site, and logo plots show mutations at sites that are strongly selected by the serum (orange) or antibody (blue). (B) Neutralization curves for some of the most strongly selected mutations against serum or antibody alone. Note that the antibody is 4F03 from Figure 2 , the human serum is that from the 65-yearold in Figure 3 , and the antibody-alone and serum-alone panels re-display data from those figures using a different color-scheme and subset of sites in the logo plots. DOI: https://doi.org/10.7554/eLife.49324.019
A B
Figure 7-figure supplement 1. Percent of viral library retaining infectivity after treatment with each serum +antibody mix. The percent of the mutant virus library that remained infectious after incubation with serum and/or antibody was determined using qPCR for each replicate of the mutational antigenic profiling. The blue points show the actual percent infectivity for each experiment in Figure 7A that used a mix of serum and antibody. The green points show the actual percent infectivity for the serum-alone selection in Figure 7A ; in the serum-antibody mix selections the serum was at the same concentrations that gave these percent infectivities. The orange points show the percent infectivity measured at each antibody concentration used in the serum-antibody mix selections; the antibody concentrations used to generate the antibody-alone selection in Figure 7A are those shown in ('lib1', 'lib2', or 'lib3') . These plots are replicate-to-replicate breakdowns of those in Figure 7A except that the logo plots are colored by the physicochemical properties of amino acids rather than using the color scheme in the main figure. Note that Figure 7A displays the median of the replicates shown here. The replicate plots for the antibody-alone and serum-alone plots in Figure 7A are in There are 16 sites under strong immune selection in our mutational antigenic profiling with human sera, and this figure shows the nine of these sites for which a new amino acid rose to 5% frequency. The numbers at the top of each plot indicate the site number, and the letters indicate the amino acid identity. The figure panels are taken from the Nextstrain real-time pathogen evolution website (Hadfield et al., 2018; Neher and Bedford, 2015) . DOI: https://doi.org/10.7554/eLife.49324.022
